ŞKŞule Çelik Kamacı

Şule Çelik Kamacı

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Şule Çelik Kamacı has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Aslı Gelincik

    Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye

    3 shared publications
  • Derya Unal

    Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul, Turkey

    3 shared publications
  • Semra Demir

    Division of Immunology and Allergy Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Türkiye

    3 shared publications
  • Bircan Erden

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    2 shared publications
  • Mehmet Emin Sezgin

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    2 shared publications
  • Merve Hormet Igde

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    2 shared publications

Latest Publications

  • Open Access

    NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria

    by Merve Hormet Igde, Pelin Korkmaz, Semra Demir, Osman Ozan Yegit, Derya Ünal, Merve Dilşad Atasever, Ayşe Feyza Aslan, Leyla Bölek, Selin Ece Güzel, Nevzat Kahveci, et al.

    Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.

  • Open Access

    Changes in Psychological Burden and Quality of Life During In Vivo Diagnostic Evaluation for Immediate Drug Hypersensitivity: A Prospective Stepwise Study

    by Ayşe Feyza Aslan, Semra Demir, Pelin Korkmaz, İlkim Deniz Toprak, Nevzat Kahveci, Merve Hörmet İğde, Mehmet Emin Sezgin, Bircan Erden, Deniz Eyice Karabacak, Şule Çelik Kamacı, et al.

    Background/Objective: The psychological impact of in vivo diagnostic procedures remains poorly understood. We assessed changes in psychological distress and drug hypersensitivity-related quality of life (QoL) throughout a diagnostic evaluation for suspected immediate drug hypersensitivity reactions (IDHRs) and aimed to identify predictors of persistent psychological burden. Methods: This single-center prospective observational longitudinal study included 100 consecutive adults undergoing evaluation for suspected IDHRs. Psychological distress and QoL were assessed using the Depression Anxiety Stress Scale-21 (DASS-21) and the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q). Assessments were performed before and after each diagnostic phase, including skin tests (STs), placebo, and drug provocation tests (DPTs). Results: The mean age was 44.2 ± 12.5 years, and women comprised 72% of the cohort. Depression, anxiety, stress, and DrHy-Q scores significantly decreased after ST, placebo, and DPT compared with baseline measurements. Across diagnostic stages, depression, anxiety, stress, and DrHy-Q scores were significantly lower during the DPT phase than during the ST and placebo phase in both pre-test and post-test measurements (p < 0.01 for pairwise comparisons). The number of prior HSRs showed a weak but significant positive correlation with DrHy-Q scores. In multivariable linear regression analysis, the number of prior HSRs was the only independent predictor of post-DPT DrHy-Q scores (β = 3.43, 95% CI 1.36–5.50, p = 0.001). Patients who avoided the provoked drug despite a negative DPT had higher DPT-post depression, anxiety, stress, and DrHy-Q scores. Conclusions: Psychological burden progressively decreased over the course of the stepwise diagnostic evaluation for suspected IDHRs, although patients with repeated reactions may benefit from additional support.

  • Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study

    by Murat Türk, Muhammed Burak Yücel, İnSu Yılmaz, Ragıp Ertaş, Ümit Murat Şahiner, Semra Demir, Aslı Gelincik, Derya Ünal, Şule Çelik Kamacı, Merve Hörmet İğDe, et al.

    Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.